Abeona Therapeutics Inc.ABEONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank72
5Y CAGR-29.1%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-29.1%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.26% |
| Q3 2025 | -12.79% |
| Q2 2025 | -2.08% |
| Q1 2025 | -11.13% |
| Q4 2024 | -35.35% |
| Q3 2024 | 3.55% |
| Q2 2024 | 12.75% |
| Q1 2024 | -57.42% |
| Q4 2023 | -60.72% |
| Q3 2023 | 44.13% |
| Q2 2023 | 12.43% |
| Q1 2023 | 16.07% |
| Q4 2022 | -106.04% |
| Q3 2022 | 24.65% |
| Q2 2022 | 34.15% |
| Q1 2022 | 54.76% |
| Q4 2021 | -192.79% |
| Q3 2021 | 10.05% |
| Q2 2021 | 15.43% |
| Q1 2021 | -743.79% |
| Q4 2020 | 84.96% |
| Q3 2020 | -12.95% |
| Q2 2020 | 28.39% |
| Q1 2020 | 7.12% |
| Q4 2019 | 21.96% |
| Q3 2019 | -19.76% |
| Q2 2019 | -1.09% |
| Q1 2019 | 11.13% |
| Q4 2018 | -87.69% |
| Q3 2018 | -0.20% |
| Q2 2018 | -121.02% |
| Q1 2018 | 23.36% |
| Q4 2017 | 21.33% |
| Q3 2017 | -35.89% |
| Q2 2017 | 14.94% |
| Q1 2017 | -72.62% |
| Q4 2016 | 14.94% |
| Q3 2016 | -28.02% |
| Q2 2016 | -23.85% |
| Q1 2016 | 12.55% |